abrdn Life Sciences Investors (NYSE:HQL) Reaches New 12-Month High – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL) hit a new 52-week high on Wednesday . The company traded as high as $18.10 and last traded at $18.1250, with a volume of 68327 shares changing hands. The stock had previously closed at $17.90.

abrdn Life Sciences Investors Stock Up 1.7%

The company’s 50 day moving average price is $16.88 and its 200-day moving average price is $16.93.

abrdn Life Sciences Investors Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th were given a $0.56 dividend. This represents a $2.24 annualized dividend and a yield of 12.3%. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. The ex-dividend date was Friday, February 20th.

Institutional Investors Weigh In On abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently modified their holdings of HQL. KPP Advisory Services LLC grew its holdings in shares of abrdn Life Sciences Investors by 5.8% in the 1st quarter. KPP Advisory Services LLC now owns 24,591 shares of the company’s stock worth $400,000 after acquiring an additional 1,354 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after purchasing an additional 1,529 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of abrdn Life Sciences Investors by 5.2% during the second quarter. NewEdge Advisors LLC now owns 34,190 shares of the company’s stock valued at $438,000 after purchasing an additional 1,690 shares during the last quarter. Uhlmann Price Securities LLC boosted its position in shares of abrdn Life Sciences Investors by 2.3% in the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock valued at $1,267,000 after purchasing an additional 1,719 shares during the period. Finally, Blue Bell Private Wealth Management LLC boosted its position in shares of abrdn Life Sciences Investors by 2.9% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 64,828 shares of the company’s stock valued at $1,005,000 after purchasing an additional 1,800 shares during the period. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.